Clinical Trial

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial is being done to develop and test a healthy eating program to reduce cancer recurrence (cancer that has come back after a period of improvement) and/or progression (cancer that is growing, spreading, or getting worse) in patients with non-muscle invasive bladder cancer (NMIBC). Researchers want to better understand how incorporating more cruciferous vegetables in the diet may reduce the risk of cancer recurrence or progression in men and women who were diagnosed with early-stage bladder cancer and compare whether extending the program can further improve bladder cancer outcomes. POW-R Health is a behavioral dietary intervention designed to modestly increase cruciferous vegetable (cruciferae) intake in patients. Cruciferous vegetables, such as cabbage, kale and broccoli, arugula, contain phytochemicals known as isothiocyanates (ITCs). Dietary ITCs exert potent anticancer activities against bladder cancer and can be rapidly metabolized, delivered to the bladder, and concentrated in the urine. Participating in the healthy eating program may reduce bladder cancer recurrence or progression in NMIBC survivors.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-12-10; most recent amendment 2026-05-07.
Status change: Not Yet Recruiting → Recruiting 2026-01-26
Status change: Recruiting → Not Yet Recruiting 2025-11-18
Status change: Not Yet Recruiting → Recruiting 2025-11-06
Status change: Recruiting → Not Yet Recruiting 2025-08-12
Status change: Not Yet Recruiting → Recruiting 2025-06-06
Trial Details
NCT Number NCT06733363
Lead Sponsor Roswell Park Cancer Institute
Collaborators: National Cancer Institute (NCI)
Conditions Non-Muscle Invasive Bladder Carcinoma, Recurrent Bladder Carcinoma, Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 1 Bladder Cancer AJCC v8
Enrollment 344 participants
Start Date 2026-01-13
Primary Completion 2028-01-13 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-08